WuXi PharmaTech (WX) Misses Q1 EPS by 9c, Offers Guidance

WuXi PharmaTech (NYSE: WX) reported Q1 EPS of $0.30, $0.09 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $146.7 million versus the consensus estimate of $145 million.

Full-Year 2014 Financial Guidance

WuXi PharmaTech announces the following full-year 2014 financial guidance:

Total net revenues of $660-670 million, the same as previous guidance
GAAP diluted earnings per ADS of $1.53-$1.58, including mark-to-market losses on foreign-exchange forward contracts of $0.20 per ADS; GAAP diluted earnings per ADS of $1.73-$1.78, excluding mark-to-market gains or losses on foreign-exchange forward contracts

Non-GAAP diluted earnings per ADS of $1.80-$1.85, including mark-to-market losses on foreign-exchange forward contracts of $0.20 per ADS; non-GAAP diluted earnings per ADS of $2.00-$2.05, excluding mark-to-market gains or losses on foreign-exchange forward contracts

Capital expenditures of about $85 million, a year-over-year increase of about 50%, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology

For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
• Logistic Properties of the Americas (LPA) Reports Q2 results